Co-Diagnostics, Inc. (CODX)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 2
Do Nothing: fundamentalScore 1 and qualitativeScore 1 are both below the required floor of 3, and CODX also fails the $5M liquidity floor.
Company overview
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Fundamental
very weakCo-Diagnostics faces high fundamental risk with going-concern doubts and heavy cash burn.
Speculative micro-cap diagnostics developer with explicit going‑concern language and a fast cash burn. Revenue is minimal versus operating costs, so near‑term financing (and likely dilution) is the central risk. Despite model-based intrinsic value outputs that look very optimistic, the operating and liquidity picture remains weak.
Sentiment
very weakSentiment is risk-off with no actionable catalysts and promotional retail chatter.
Last ~14d coverage swung negative (polarity_score ≈ -0.23 vs +0.38 baseline) around the announced Q2 2026 results and fresh investor-litigation headlines, shifting focus back to liquidity/dilution risk. Severe red-flag cap applied due to ongoing going‑concern/substantial‑doubt disclosures.
Technical
weakThe stock is oversold but remains below key trend measures with weak momentum.
The chart scores 2/5: CODX is bouncing from an oversold flush, but the primary structure is still bearish. Price 1.21 remains below SMA20/50/200 and EMA9/21, and MACD stays below zero despite a small positive histogram.
You’re looking at 2026-08-23 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.